Oral anticancer agent medication adherence by outpatients

  • Authors:
    • MIchio Kimura
    • EIseki Usami
    • Mina Iwai
    • Toshiya Nakao
    • Tomoaki Yoshimura
    • Hiromi Mori
    • Tadashi Sugiyama
    • Hitomi Teramachi
  • View Affiliations

  • Published online on: August 26, 2014     https://doi.org/10.3892/ol.2014.2480
  • Pages: 2318-2324
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present study, medication adherence and factors affecting adherence were examined in patients taking oral anticancer agents. In June 2013, 172 outpatients who had been prescribed oral anticancer agents by Ogaki Municipal Hospital (Ogaki, Gifu, Japan) completed a questionnaire survey, with answers rated on a five‑point Likert scale. The factors that affect medication adherence were evaluated using a customer satisfaction (CS) analysis. For patients with good and insufficient adherence to medication, the median ages were 66 years (range, 21‑85 years) and 73 years (range, 30‑90 years), respectively (P=0.0004), while the median dosing time was 131 days (range, 3‑3,585 days) and 219 days (24‑3,465 days), respectively (P=0.0447). In 36.0% (62 out of 172) of the cases, there was insufficient medication adherence; 64.5% of those cases (40 out of 62) showed good medication compliance (4‑5 point rating score). However, these patients did not fully understand the effects or side‑effects of the drugs, giving a score of three points or less. The percentage of patients with good medication compliance was 87.2% (150 out of 172). Through the CS analysis, three items, the interest in the drug, the desire to consult about the drug and the condition of the patient, were extracted as items for improvement. Overall, the medication compliance of the patients taking the oral anticancer agents was good, but the medication adherence was insufficient. To improve medication adherence, a better understanding of the effectiveness and necessity of drugs and their side‑effects is required. In addition, the interest of patients in their medication should be encouraged and intervention should be tailored to the condition of the patient. These steps should lead to improved medication adherence.

Introduction

Medication adherence is often defined as follows: Subsequent to sufficient explanation of the effects and side-effects of medication, the patient agrees to be treated with the medication, understands the significance of the medication and continues to take the medication voluntarily (1). By contrast, the conventionally used definition of medication compliance refers to the patient taking medication in the amount and at the times directed by pharmacists and physicians. Cancer treatment through oral anticancer agents has the advantage of ease of delivery, but since medication management is left to the family or patient, medication adherence can be a problem. It is important that the patient understands the effects of the prescribed drugs, the side-effects and the methods to assuage these, and that they also understand that medication adherence can lead to effective treatment, safety and continuity in cancer chemotherapy. A lack of medication adherence can decrease treatment efficiency, change the seriousness of the side-effects and increase the number of hospitalizations and doctor visits, all of which can lead to higher medical costs (2,3). Therefore, the improvement of medication adherence is an important component in cancer treatment.

Patients who are diagnosed with cancer are generally observed as having strong reasons for adhering to treatment, as a lack of adherence could lead to serious side-effects, cancer relapse or mortality. Despite the serious effects of non-adherence, previous studies have indicated that the medication adherence rate in cancer patients is not 100% (48).

Research into medication adherence in patients taking oral anticancer agents has generally focused on a specific disease, such as chronic myeloid leukemia (CML) or breast cancer, and the disease-specific medicine (48). At present, neither the adherence to tegafur/gimeracil/oteracil potassium (S-1) and multiple tyrosine kinase inhibitors nor the level of consciousness behind non-adherence or non-compliance has been examined. Therefore, a questionnaire survey was conducted to evaluate the factors that affect medication adherence in patients taking oral anticancer agents. The results of the survey were explored using a customer satisfaction (CS) analysis.

Materials and methods

Participants

The participants in the present study were outpatients undergoing treatment with oral anticancer agents at Ogaki Municipal Hospital (Ogaki, Gifu, Japan) in June 2013. A self-report questionnaire survey was administered to these patients, and those who had difficulty reading or writing were assisted. The questionnaires were distributed to 182 individuals. The return rate for the questionnaires was 94.5% (172 out of 182).

The present study was approved by the Institutional Review Board of Ogaki Municipal Hospital and was explained in a handout distributed to participants prior to obtaining their informed consent.

Measures
Questionnaire survey items

The questionnaire items are shown in Table I. The survey items included: Medication adherence (six items total), with one item each for the dosing method, effect of drugs, side-effects, understanding of the treatment method, treatment policy and compliance; personality (three items); and factors potentially affecting adherence, namely, the living environment (one item), awareness of medication dosage (three items), knowledge of the drug (six items), daily schedule (two items), understanding of the disease (one item), sense of trust (two items), expectations and attitude (two items) and condition (one item). The participants were instructed to include all currently prescribed medications in one of the dosing method questions.

Table I

Questionnaire.

Table I

Questionnaire.

A questionnaire relating to taking your medication
Please answer the following questions by indicating the answers which apply to you (please circle the number or position which applies to you)

QuestionYesI think soI cannot say either wayI do not think soNo
1. I understand how to take the medication54321
2. I know the effect (efficacy) of the medication54321
3. I know the side effects of the medication54321
4. I understand the current therapy54321
5. I agree with the current treatment policy54321
6. I have forgotten to take the medication or I have mistakenly taken the medicationNeverRarelyI cannot say either wayOccasionallyOften
7. Currently, what is the composition of your household?I live aloneHusband and wifeOther
8. I take care not to forget my medication54321
9. I think I take a lot of medications54321
10. Dosing times are complicated or awkward54321
11. The current treatment costs (prescription charges) are an economic burden54321
12. I believe the medication is necessary for me54321
13. I believe the medication is effective54321
14. I have actively researched about my medication54321
15. I worry about side effects54321
16. I would like to talk to someone further about the medication54321
17. I have a regular daily schedule54321
18. I eat regular meals54321
19. I am methodical54321
20. I am a worrier54321
21. I tend to find things bothersome54321
22. I have a good understanding of my disease54321
23. I trust the attending physician54321
24. I trust the pharmacist54321
25. I hope that the medication is valuable in curing the disease or that it will be able to improve my quality of life54321
26. I have a positive attitude towards the disease54321
27. What is your general condition (health)?Very goodGoodAverageBadVery bad

Thank you for your cooperation

The survey items were rated on a five-point Likert scale, with 5 being ‘Yes’, 4 being ‘I think so’, 3 being ‘I cannot say either way’, 2 being ‘I do not think so’ and 1 being ‘No’. Items 9–11 were reverse-scored.

Using the scores on the medication adherence scale of the questionnaire, the participants were divided into two groups: The ‘good medication adherence’ group, consisting of those who adhered to medication regimens, with a score ≥4 on all items; and the ‘insufficient medication’ group, which consisted of those who did not adhere, classified as participants who scored ≤3 on all items. The scores across the two groups were compared for each variable. All data, including the evaluation score value, the number of drugs taken and the dosing time, are presented as the median value within the range.

Evaluation of medication adherence by CS analysis

CS object variable analysis was performed with the lowest point for each item in medication adherence in order to investigate adherence factors, and the questions associated with the factors that potentially affected medication adherence were analyzed to determine an explanatory variable. For the questions associated with the factors that potentially affected medication adherence, CS analysis was performed with the items that possessed significant differences between the good and insufficient groups.

The CS analysis graph was plotted on two-dimensional coordinates. The average deviations of the scores for each item on the questionnaire were plotted on the vertical axis of the CS analysis graph, while the association value (correlation coefficient deviation value) between adherence factors and the individual evaluation was plotted on the horizontal axis. In the CS analysis graph, factors with a high score and a high degree of influence on adherence are plotted in the first quadrant, termed the emphasis maintenance field. Factors with a high score and low degree of influence on adherence are plotted in the second quadrant, termed the maintenance field. Factors with a low score and low degree of influence on adherence are plotted in the third quadrant, termed the improvement field, and factors with a low score and high degree of influence on adherence are plotted in the fourth quadrant, termed the priority improvement field. The CS analysis improvement degree for each question was calculated. This degree is an index indicating the magnitude of the effect a factor has on adherence. If the CS analysis improvement degree is positive, improvement is required in the items with a score of five points or greater. Conversely, a negative CS analysis improvement degree would indicate that improvement is not necessary.

Statistical analysis

The Mann-Whitney U test was used to compare the two groups. In all statistical tests, P<0.05 was considered to indicate a statistically significant difference. For the CS analysis, the statistical software, EXCEL® Quality Management (Esumi Co., Ltd., Tokyo, Japan), was used.

Results

Drugs

The drugs represented in the current study and the number of patients taking those drugs were S-1 (n=83), capecitabine (n=26), molecularly-targeted drugs, such as sorafenib (n=45), tegafur-uracil combination (n=10) and other drugs, including cyclophosphamide, mercaptopurine and hydroxycarbamide (n=10).

Evaluation of medication adherence

Good medication adherence was found for 64.0% of the patients (110 out of 172). The scores of the patients with insufficient adherence to medication are shown in Fig. 1. The scores [median (range)] were 5.0 (3.0–5.0) for the dosing method, 5.0 (1.0–5.0) for the effect of the drug, 3.0 (1.0–5.0) for the side-effects, 5.0 (2.0–5.0) for the understanding of the treatment method, 5.0 (1.0–5.0) for the treatment policy and 4.0 (2.0–5.0) for compliance.

In 36.0% (62 out of 172) of the cases, there was insufficient medication adherence. However, 64.5% of those cases (40 out of 62) had good medication compliance, with a score of 4–5 points. It is likely that these patients did not fully understand the effects of the drugs or side-effects, giving a score of three points or less on these items. However, the percentage of patients with good medication compliance was 87.2% (150 out of 172).

Evaluation of patient demographic factors that affect medication adherence

The patient demographics that potentially affected medication adherence are shown in Table II. Patients with good and insufficient adherence to medication had a median age of 66 years (range, 21–85 years) and 73 years (range, 30–90 years), respectively (P=0.0004). The median number of drugs taken was four for each group (good adherence range, 1–10 drugs; insufficient adherence range, 1–14 drugs; P=0.0401) and the length of time on the medication was 131 days (range, 3–3,585 days) in the good adherence to medication group and 219 days (24–3,465 days) (P=0.0447) in the insufficient adherence group.

Table II

Score of patient attribute factors that affect medication adherence.

Table II

Score of patient attribute factors that affect medication adherence.

Medication adherence

FactorGood (n=109)Insufficient (n=62)P-value
Age, yearsa66 (21–85)73 (30–90)0.0004
Gender, n0.7249
 Male6034
 Female4928
Number of drugs taken (range)a,b4 (1–10)4 (1–14)0.0401
Dosing time, days (range)a131 (3–3585)219 (24–3465)0.0447
Stage, n0.6609
 Adjuvant2919
 Progressive8043
Family, n0.5692
 Living alone9654
 Other138

a Statistically significant difference.

b Includes medication other than anticancer drugs.

Evaluation of factors that affect medication adherence

The scores associated with factors that affected medication adherence are shown in Table III. For patients with good or insufficient adherence to medication, there were significant differences (P<0.05) in nine items on the following subscales: Awareness of dosing (one out of three items), awareness about the drug (three out of six items), understanding the disease (one out of one item), sense of trust (two out of two items), expectations and attitudes (one out of two items) and the condition of the patient (one out of one item).

Table III

Score of factors that affect medication adherence.

Table III

Score of factors that affect medication adherence.

Median medication adherence score (range)

TopicQuestion numberQuestionGood (n=109)Insufficient (n=62)P-value
Living environment7Currently, what is the composition of your household?2 (1–3)3 (1–3)0.9915
Awareness about dosing8I take care not to forget my medication5 (4–5)5 (3–5)0.4968
9I think I take a lot of medications2 (1–5)3 (1–5)0.0116a
10Dosing times are complicated or awkward1 (1–5)1 (1–5)0.1819
Awareness about drug11The current treatment costs (prescription charges) are an economic burden3 (1–5)3 (1–5)0.6207
12I believe the medication is necessary for me5 (1–5)5 (1–5)0.1199
13I believe the medication is effective5 (2–5)5 (2–5)0.0358a
14I have actively researched about my medication2 (1–5)1 (1–5)0.0397a
15I worry about side effects4 (1–5)4 (1–5)0.2185
16I would like to talk to someone further about the medication3 (1–5)2 (1–5)0.0413a
Daily schedule17I have a regular daily schedule5 (1–5)5 (2–5)0.1528
18I eat regular meals5 (2–5)5 (2–5)0.3231
Personality19I am methodical4 (1–5)4 (1–5)0.1716
20I am a worrier4 (1–5)3 (1–5)0.1143
21I tend to find things bothersome3 (1–5)3 (1–5)0.4135
Understanding of the stage of the disease22I have a good understanding of my disease5 (2–5)5 (1–5)0.0262a
Sense of trust23I trust the attending physician5 (3–5)5 (1–5)0.0262a
24I trust the pharmacist5 (2–5)5 (1–5)0.0345a
Expectations and attitude25I hope that the medication is valuable in curing the disease or that it will be able to improve my quality of life5 (2–5)5 (2–5)0.3717
26I have a positive attitude towards the disease5 (3–5)5 (1–5)0.0245a
Condition27What is your general condition (health)?3 (2–5)3 (2–5)0.0196a

a Statistically significant difference.

CS analysis on the improvement of medication adherence

The CS analysis graph is shown in Fig. 2 and the data obtained from CS analysis are shown in Table IV. From the CS analysis, three items, namely interest in the drug, desire to consult about the drug and condition of the patient, were found to be areas requiring improvement (degree of improvement; 11.00, 8.50, and 5.77, respectively).

Table IV

Data obtained from CS analysis.

Table IV

Data obtained from CS analysis.

Question numberTopicAverage value of explanatory variablesCorrelation coefficientAverage value of explanatory variables, deviation valueCorrelation coefficient, deviation valueAngleDistanceDegree of improvement
14Interest in druga2.290.154435.2850.8341.7714.74311.00
16Desire to consult about druga2.470.136737.0949.1248.9112.9378.50
27Condition of patienta3.450.197646.8655.0112.905.9165.77
24Confidence in pharmacist4.440.204056.7455.6395.098.782−0.78
22Understanding of disease4.580.206258.2055.8599.5110.068−1.66
23Confidence in doctor4.810.224160.4257.5898.9712.884−2.01
13Drug effect4.450.145556.8549.97135.296.853−4.87
26Positive attitude4.780.179060.1953.22117.4810.681−4.93
9Number of drugs taken2.60−0.134938.3822.80111.8629.576−11.01

a Items requiring improvement according to the customer satisfaction (CS) analysis.

Discussion

Numerous studies have examined medication adherence in patients taking oral anticancer agents for CML and breast cancer (5,713). These studies have reported considerably different medication adherence rates; for example, the adherence rate of patients with CML was 14.2% in a study by Noens et al (7), but 98% in a study by Marin et al (5). Thus, it may be that differences in medication adherence rates depend largely on the survey method. In the present study, the percentage of patients with good medication adherence was not high (64.0%), however, the percentage of patients with good medication compliance was 87.2%. As numerous patients took the medication as directed, it can be concluded that the medication compliance of patients taking oral anticancer agents was good, but that the medication adherence, according to the definition of the present study, was insufficient.

Medication non-adherence in cancer chemotherapy can lead to an increase in the seriousness of side-effects, a deterioration in general health and a worse prognosis. Therefore, it is important to learn the causes of non-adherence to improve overall adherence.

The present study found that medication adherence decreased with age. Hasegawa et al (14) and Tsuboi et al (15) reported that medication adherence is higher in elderly patients compared with young patients. These differences may be accounted for by differences in the participants, but since this is not the only possibility, differences in participants should be a topic for future investigations. In addition, the patients with a longer course of medication were more likely to be in the insufficient medication adherence category. Ziller et al (16) reported that when patients received supplementary information, medication adherence was good after 12 months. Therefore, in cases with a long course of medication, patient guidance and information is important.

With regard to the factors affecting medication adherence, nine items that had a significant effect on adherence were observed in the present study: The number of drugs taken, the effect of the drug, researching the medication, consulting with the doctor or pharmacist about the drug, the understanding of the disease, confidence in the doctor, confidence in the pharmacist, a positive attitude and the condition of the patient. Russmann et al (17) reported that good relationships between patients, families and medical personnel improved medication adherence. In the present study, similarly, confidence in the doctor or pharmacist affected medication adherence. However, if the guidance provided to the patient is insufficient and the patient does not understand the supportive care, it may lead to a decrease in the quality of life and an increase in the frequency of doctor visits and re-hospitalization due to improper or inadequate medication, including the use of antiemetics in supportive care (18).

Regarding the factors associated with treatment, the effect of the frequency, duration and number of drugs taken on medication adherence must be considered. It has been reported that an administration frequency of more than three times a day reduces medication adherence significantly (19). In the present study, the majority of the drugs were to be taken once or twice a day. Therefore, it was assumed that the effect of the medication administration frequency would be small. However, the patients with insufficient medication adherence felt that they take a large number of drugs, particularly when drugs were prescribed at the same time as the anticancer medication. Therefore, all drugs taken, not only anticancer agents, should be considered, as this could lead to an improved understanding of patient-specific issues and improve the directions offered to patients.

The attitude of a patient towards the disease and treatment is an important factor. In the current study, patients with good medication adherence were interested in learning about the medicine and disease, and actively participated in their treatment. It was also found that a positive attitude towards the disease could affect medication adherence. If patients express a positive attitude towards their disease, their willingness to participate in the monitoring of side-effects may be higher.

The health of the patients also affected medication adherence. In the present study, poor medication adherence was associated with poor patient health. It could be hypothesized that adherence to the treatment plan may be prevented by having poor health.

According to the CS analysis, the items requiring the greatest improvement were the interest in the drug, the desire to consult about the drug and the condition of the patient. The interest of patients in their own medication leads to the improvement of medication adherence, which has been demonstrated to alleviate anxiety; guiding these patients in the management of side-effects is necessary. In addition, interventions tailored to the condition of each patient are necessary to ensure that the proper medication regimen is fully adhered to. Winkeljohn (20) reported that health care providers should work with patients on intervention plans, including discussing anxiety or answering treatment questions, providing education about the symptoms of the disease and teaching the management of medication side-effects. Patient education and continuing guidance can be considered beneficial when delivered at appropriate times using appropriate methods.

In summary, medical personnel must be aware of the number of medications taken by the patient, the course of the medication and the age of the patient when they instruct patients undergoing anticancer treatments on the use of oral anticancer agents. Future studies are necessary for an improved understanding of the effect and necessity of drugs and their side-effects. In addition, interventions and instructions must begin to be tailored to the condition of each patient, as this would encourage patients to take a greater interest in their own medication. These actions may lead to improved medication adherence and enhance the efficacy, safety and continuity of oral anticancer treatments.

References

1 

Owashi T and Uejima K: Adherence from compliance. Gekkan yakuji. 50:373–376. 2008.(In Japanese).

2 

Wu EQ, Guerin A, Yu AP, et al: Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukaemia. Curr Med Res Opin. 26:2861–2869. 2010.

3 

Reginster JY: Adherence and persistence: impact on outcomes and health care resources. Bone. 38(Suppl 2): S18–S21. 2006.

4 

Macintosh PW, Pond GR, Pond BJ, Leung V and Siu LL: A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl). 16:380–386. 2007.

5 

Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 28:2381–2388. 2010.

6 

Nilsson JL, Andersson K, Bergkvist A, et al: Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care (Engl). 15:235–237. 2006.

7 

Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukaemia: the ADAGIO study. Blood. 113:5401–5411. 2009.

8 

Partridge AH, Archer L, Kornblith AB, et al: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 28:2418–2422. 2010.

9 

Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 28:4120–4128. 2010.

10 

Lebovits AH, Strain JJ, Schleifer SJ, et al: Patient noncompliance with self-administered chemotherapy. Cancer. 65:17–22. 1990.

11 

Mayer EL, Partridge AH, Harris LN, et al: Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 117:615–623. 2009.

12 

McCowan C, Shearer J, Donnan PT, et al: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 99:1763–1768. 2008.

13 

Moore S: Nonadherence in patients with breast cancer receiving oral therapies. Clin J Oncol Nurs. 14:41–47. 2010.

14 

Hasegawa K, Kuritani Y, Adachi A, et al: Improvement of drug compliance and pharmaceutical care - types of drug and dosing regimens desired by patients. Iryouyakugaku. 34:800–804. 2008.(In Japanese).

15 

Tsuboi K, Teramachi H, Kuzuya Y, et al: Survey of the patients’ consciousness affecting medication adherence. Iryouyakugaku. 38:522–533. 2012.(In Japanese).

16 

Ziller V, Kyvernitakis I, Knöll D, et al: Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study. BMC Cancer. 13:4072013.

17 

Russmann S, Curkovic I and Huber M: Adverse reactions and risks associated with non compliance. Ther Umsch. 67:303–307. 2010.(In German).

18 

Ruddy K, Mayer E and Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 59:56–66. 2009.

19 

Lee CR, Nicholson PW, Souhami RL and Deshmukh AA: Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol. 10:1007–1013. 1992.

20 

Winkeljohn D: Adherence to oral cancer therapies: nursing interventions. Clin J Oncol Nurs. 14:461–466. 2010.

Related Articles

Journal Cover

November-2014
Volume 8 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kimura M, Usami E, Iwai M, Nakao T, Yoshimura T, Mori H, Sugiyama T and Teramachi H: Oral anticancer agent medication adherence by outpatients. Oncol Lett 8: 2318-2324, 2014.
APA
Kimura, M., Usami, E., Iwai, M., Nakao, T., Yoshimura, T., Mori, H. ... Teramachi, H. (2014). Oral anticancer agent medication adherence by outpatients. Oncology Letters, 8, 2318-2324. https://doi.org/10.3892/ol.2014.2480
MLA
Kimura, M., Usami, E., Iwai, M., Nakao, T., Yoshimura, T., Mori, H., Sugiyama, T., Teramachi, H."Oral anticancer agent medication adherence by outpatients". Oncology Letters 8.5 (2014): 2318-2324.
Chicago
Kimura, M., Usami, E., Iwai, M., Nakao, T., Yoshimura, T., Mori, H., Sugiyama, T., Teramachi, H."Oral anticancer agent medication adherence by outpatients". Oncology Letters 8, no. 5 (2014): 2318-2324. https://doi.org/10.3892/ol.2014.2480